SciELO - Scientific Electronic Library Online

 
vol.139 issue10Catheter associated bacteremia caused by Ochrobactrum anthropi in a patient on hemodialysis: Report of one caseTandem mass spectrometry as screening for inborn errors of metabolism author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

Share


Revista médica de Chile

Print version ISSN 0034-9887

Abstract

BERKOVITS, Alejandro et al. New oral anticoagulant drugs. Rev. méd. Chile [online]. 2011, vol.139, n.10, pp.1347-1355. ISSN 0034-9887.  http://dx.doi.org/10.4067/S0034-98872011001000016.

Thromboembolic disease (TED) is the leading cause of morbidity and mortality worldwide. The hallmark of oral long-term anticoagulant therapy has been the use of vitamin K antagonists, whose anticoagulant effect is exerted inhibiting vitamin K epoxide reductase. Warfarin and acenocoumarol are the most commonly used. In the last five years several new drugs for long term anticoagulation have been developed, which can inhibit single clotting factors with the purpose of improving drug therapeutic range and, ideally, minimizing bleeding risks. This review addresses the state of the art on the clinical use of inhibitors of activated factor X and thrombin.

Keywords : Anticoagulants; Haemostasis; Thrombosis.

        · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License